{"id":709,"date":"2024-08-13T21:27:40","date_gmt":"2024-08-13T13:27:40","guid":{"rendered":"https:\/\/flcube.com\/?p=709"},"modified":"2024-10-13T21:59:48","modified_gmt":"2024-10-13T13:59:48","slug":"ocumension-therapeutics-partners-with-alcon-laboratories-secures-rights-to-ophthalmic-products-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=709","title":{"rendered":"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China"},"content":{"rendered":"\n

Ocumension Therapeutics (HKG: 1477<\/a>), a biopharmaceutical company based in China, has entered into a strategic partnership with Alcon Laboratories Inc., a global leader in eye care and a subsidiary of Novartis. Under the terms of the agreement, Alcon will provide Ocumension with research and development, manufacturing, and commercialization rights for several of its established products and one clinical-stage candidate within the Chinese market. In exchange, Ocumension will issue 139,159,664 new shares to Alcon, representing a 16.71% equity stake, thereby making Alcon one of Ocumension’s key shareholders. The partnership also includes mutual priority negotiation rights for future pipeline products.<\/p>\n\n\n\n

As outlined in the press release, Ocumension is acquiring all rights in China for Alcon’s Tears Natural Forte (dextran, hypromellose, glycerol), Bion Tears (dextran), Alcaine (proparacaine), Fluorescite (fluorescein), and Cyclogyl (cyclopentolate). Following a transition period, Ocumension will take over the manufacturing of these products. Additionally, Ocumension secures commercialization rights in China for Systane Ultra (polyethylene glycol) and development, manufacturing, and commercial rights for AR-15512, an innovative topical drug candidate for dry eye that is currently in development.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[936,156,44],"class_list":["post-709","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1477","tag-ocumension-therapeutics","tag-ophthalmology"],"yoast_head":"\nOcumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic partnership with Alcon Laboratories Inc., a global leader in eye care and a subsidiary of Novartis. Under the terms of the agreement, Alcon will provide Ocumension with research and development, manufacturing, and commercialization rights for several of its established products and one clinical-stage candidate within the Chinese market. In exchange, Ocumension will issue 139,159,664 new shares to Alcon, representing a 16.71% equity stake, thereby making Alcon one of Ocumension's key shareholders. The partnership also includes mutual priority negotiation rights for future pipeline products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=709\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=709\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-13T13:27:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T13:59:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=709#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=709\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China\",\"datePublished\":\"2024-08-13T13:27:40+00:00\",\"dateModified\":\"2024-10-13T13:59:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=709\"},\"wordCount\":190,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1477\",\"Ocumension Therapeutics\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=709#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=709\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=709\",\"name\":\"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-13T13:27:40+00:00\",\"dateModified\":\"2024-10-13T13:59:48+00:00\",\"description\":\"Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic partnership with Alcon Laboratories Inc., a global leader in eye care and a subsidiary of Novartis. Under the terms of the agreement, Alcon will provide Ocumension with research and development, manufacturing, and commercialization rights for several of its established products and one clinical-stage candidate within the Chinese market. In exchange, Ocumension will issue 139,159,664 new shares to Alcon, representing a 16.71% equity stake, thereby making Alcon one of Ocumension's key shareholders. The partnership also includes mutual priority negotiation rights for future pipeline products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=709#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=709\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=709#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China - Insight, China's Pharmaceutical Industry","description":"Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic partnership with Alcon Laboratories Inc., a global leader in eye care and a subsidiary of Novartis. Under the terms of the agreement, Alcon will provide Ocumension with research and development, manufacturing, and commercialization rights for several of its established products and one clinical-stage candidate within the Chinese market. In exchange, Ocumension will issue 139,159,664 new shares to Alcon, representing a 16.71% equity stake, thereby making Alcon one of Ocumension's key shareholders. The partnership also includes mutual priority negotiation rights for future pipeline products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=709","og_locale":"en_US","og_type":"article","og_title":"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=709","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-13T13:27:40+00:00","article_modified_time":"2024-10-13T13:59:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=709#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=709"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China","datePublished":"2024-08-13T13:27:40+00:00","dateModified":"2024-10-13T13:59:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=709"},"wordCount":190,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1477","Ocumension Therapeutics","Ophthalmology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=709#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=709","url":"https:\/\/flcube.com\/?p=709","name":"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-13T13:27:40+00:00","dateModified":"2024-10-13T13:59:48+00:00","description":"Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic partnership with Alcon Laboratories Inc., a global leader in eye care and a subsidiary of Novartis. Under the terms of the agreement, Alcon will provide Ocumension with research and development, manufacturing, and commercialization rights for several of its established products and one clinical-stage candidate within the Chinese market. In exchange, Ocumension will issue 139,159,664 new shares to Alcon, representing a 16.71% equity stake, thereby making Alcon one of Ocumension's key shareholders. The partnership also includes mutual priority negotiation rights for future pipeline products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=709#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=709"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=709#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=709"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/709\/revisions"}],"predecessor-version":[{"id":6212,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/709\/revisions\/6212"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}